CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1995; 45:179
doi: 10.3322/canjclin.45.3.179
© 1995 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matthay, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matthay, K. K.

CA: A Cancer Journal for Clinicians, Vol 45, Issue 3 179-192, Copyright © 1995 by American Cancer Society

ARTICLES

Neuroblastoma: a clinical challenge and biologic puzzle

K. K. Matthay
University of California School of Medicine, San Francisco, USA.

Neuroblastoma is the third most common malignancy in childhood and accounts for at least 15 percent of cancer-related deaths in children. The varied clinical behavior of this disease, ranging from spontaneous regression in some to progression while under aggressive therapy in others, has been associated with various biologic differences, providing insight into pathophysiology and possibilities for more specific treatments. This article reviews the epidemiology, pathophysiology, clinical evaluation, and treatment of neuroblastoma.


This article has been cited by other articles:


Home page
 The OncologistHome page
G. Khanna, D. Bushnell, and M. S. O'Dorisio
Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
Oncologist, April 1, 2008; 13(4): 382 - 389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. P. McKenzie, M. K. Danks, R. W. Kriwacki, and L. C. Harris
p21Waf1/Cip1 Dysfunction in Neuroblastoma: A Novel Mechanism of Attenuating G0-G1 Cell Cycle Arrest
Cancer Res., July 1, 2003; 63(13): 3840 - 3844.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
G. J. Lonergan, C. M. Schwab, E. S. Suarez, and C. L. Carlson
From the Archives of the AFIP : Neuroblastoma, Ganglioneuroblastoma, and Ganglioneuroma: Radiologic-Pathologic Correlation
RadioGraphics, July 1, 2002; 22(4): 911 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. P. McKenzie, S. M. Guichard, D. S. Middlemas, R. A. Ashmun, M. K. Danks, and L. C. Harris
Wild-Type p53 Can Induce p21 and Apoptosis in Neuroblastoma Cells But the DNA Damage-induced G1 Checkpoint Function
Clin. Cancer Res., December 1, 1999; 5(12): 4199 - 4207.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. B. Chang, S. P. Persengiev, J. G. de Diego, M. P. Sacristan, D. M. Zanca, and D. L. Kilpatrick
Proximal Promoter Sequences Mediate Cell-specific and Elevated Expression of the Favorable Prognosis Marker TrkA in Human Neuroblastoma Cells
J. Biol. Chem., January 2, 1998; 273(1): 39 - 44.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by American Cancer Society.